Abstract
Background During the COVID-19 pandemic participatory digital syndromic surveillance systems proved itself, as it is scalable, flexible and function independent from the health care system or health care seeking behaviour. A limitation of syndromic surveillance is the inability of pathogen identification. We describe our experiences regarding integrating self-swabs with centralized testing into a participatory syndromic surveillance system in the Netherlands (Infectieradar).
Methods In the 2022/2023 winter season Infectieradar was extended to include nose- and throat swabs. Participants received test-kits including SARS-CoV-2 antigen tests for home use as well as nose- and throat swabs. All SARS-CoV-2 positive participants and a random sample of symptomatic SARS-CoV-2 self-test negative participants were asked to return a nose- and throat swab by regular post. Self-test negative swabs were tested by multiplex-PCR on 22 pathogens, including SARS-CoV-2. Self-test SARS-CoV-2 positive samples with a Ct-value < 30 were sequenced for variant analysis.
Results Over 17,000 participants were included in the study. We collected 1,475 (median: 37 per week) swabs from participants with positive and 4,096 swabs (median: 136 per week) from participants with negative SARS-CoV-2 antigen self-tests. Of the swabs following a negative self-test, 47.7% tested positive in the multiplex-PCR, and rhinovirus/enterovirus was the most frequently detected pathogen (24.5%). Self-test SARS-CoV-2 positivity was laboratory-confirmed in 96.1% of swabs and showed parallel variant distributions as the national SARS-CoV-2 variant surveillance.
Conclusion This large-scale, centralized participatory surveillance system provides a comprehensive approach for performing syndromic and virological surveillance in the general population, including respiratory pathogen detection by self-test or multiplex-PCR. Given the continuous collection of samples among those who don’t seek care, the system provides valuable insights into circulating respiratory pathogens and is part of an answer on how to study the transmission, competition, virulence and evolution of circulating pathogens in interpandemic periods.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Yes
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The research protocol was shared with the Medical Ethics Review Committee Utrecht, and an official waiver for ethical approval (reference number: WAG/avd/20/008757 protocol 20-131) was obtained given the nature of data collection. Participants had to agree to the privacy statement upon registration, which described the processing of personal data and research results, website security measures taken, and how to file a complaint. Additionally, they had to give consent to participate in the study. Participants were eligible to withdraw from the study at any time.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Not all data cannot be shared publicly because of legal constrains. Data underlying the results are also available on www.infectieradar.nl/results and data requests can be send to infectieradar{at}rivm.nl.
Abbreviations
- ARI
- Acute Respiratory Infection
- BRP
- Basis Registratie Persoonsgegevens
- COVID-19
- coronavirus disease
- GP
- general practitioner
- ILI
- influenza like illness
- IQR
- interquartile range
- RIVM
- Rijksinstituut voor Volksgezondheid en Milieu SARS-CoV-2 Severe Acute Respiratory Syndrome Coronavirus 2
